Cytolytic Too: Granzyme B-expressing Human ILC2s Mediate Tumor Rejection
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Vivier E, Artis D, Colonna M, Diefenbach A, Di Santo J, Eberl G
. Innate Lymphoid Cells: 10 Years On. Cell. 2018; 174(5):1054-1066.
DOI: 10.1016/j.cell.2018.07.017.
View
2.
Ebbo M, Crinier A, Vely F, Vivier E
. Innate lymphoid cells: major players in inflammatory diseases. Nat Rev Immunol. 2017; 17(11):665-678.
DOI: 10.1038/nri.2017.86.
View
3.
Spits H, Mjosberg J
. Heterogeneity of type 2 innate lymphoid cells. Nat Rev Immunol. 2022; 22(11):701-712.
PMC: 8966870.
DOI: 10.1038/s41577-022-00704-5.
View
4.
Jou E, Rodriguez-Rodriguez N, Ferreira A, Jolin H, Clark P, Sawmynaden K
. An innate IL-25-ILC2-MDSC axis creates a cancer-permissive microenvironment for mutation-driven intestinal tumorigenesis. Sci Immunol. 2022; 7(72):eabn0175.
PMC: 7612821.
DOI: 10.1126/sciimmunol.abn0175.
View
5.
Moral J, Leung J, Rojas L, Ruan J, Zhao J, Sethna Z
. ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity. Nature. 2020; 579(7797):130-135.
PMC: 7060130.
DOI: 10.1038/s41586-020-2015-4.
View